drugset / Trial / NCT00661401

Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin

NCT00661401

NaSingle-groupOpen-labelTreatment

Summary

Objective: Measure serum IgG antibody to Streptococcus pneumoniae serotypes 1, 3, 5, 6B, 9V e 14, Haemophilus influenzae type b and tetanus toxoid in patients with primary antibody deficiencies who were treated with subcutaneous immunoglobulin infusions.

Timeline

Start
2002-01
Primary completion
2002-11
Completion
2002-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 57 mg/kg Subcutaneous
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 132 mg/kg Subcutaneous